FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?

Beep Beep. Hey intern the patient’s blood pressure is 160/95. Do you want to do something. No. The answer is no. But honestly we have all been guilted into ordering some clonidine or god forbid some IV hydralazine. Stop it. Just stop it. Join the filtrate as we dissect a recent study looking at this issue with the lead author.

NephMadness prides itself on not repeating topics. Most topics don’t get revisited for years after a single appearance. But one region stands alone. One region is making its fourth appearance in the 12 year history of NephMadness! That region is Animal House! Modern medical education doesn’t go to the comparative physiology well very often. So when we do, it is always fresh and exciting. Join the Filtrate as we explore the fascinating world of the Gila Monster and Mourning Dove.

So this one has been on the hard drive gathering dust for quite awhile. There were significant technical problems (in other words, Joel screwed up. But the episode is now complete and despite some obvious stutters, it turned out pretty good.)

The fluids wars have been going back and forth and now have another big win. This time in transplant.

On Friday of #KidneyWk, at the City Winery in Philadelphia, The Filtrate collaborated with The Curbsiders to do a live show in front of dozens of fans. Freely Filtered is proud to get to play a role in one of these moments. Amit Garg, friend of the Pod, invited Freely Filtered into the tent to record a podcast on his High Impact and Late Breaking Clinical Trial for simultaneous release with his presentation. Here is that podcast… How do we move the needle on living donor transplants? The...

We love Kidney Week and the quintessential event at Kidney Week is the Late Break and High Impact Clinical Trial Sessions. Here we see the cutting edge of science revealed. We get to be first when years of work are revealed to the world. And one of the coolest ways for a study to be revealed is with simultaneous publication in a high-impact journal. Freely Filtered is proud to get to play a role in one of these moments. Amit Garg, friend of the Pod, invited Freely Filtered into the tent to...

Inaxaplin is a small molecule that is in trials for APOL1 associated kidney disease. Genome guided medicine comes to nephrology.

Bicarbonate did not slow the loss of GFR in this well done Swiss, single-blind study of transplant patients. The Filtrate: Joel Topf Nayan Arora Swapnil Hiremath Pirya Yenebere With Special Guest: Nav Tangri nephrologist and epidemiology at the University of Manitoba Editor: Nayan Arora Show Notes: Arsenal FC The London study that kicked it all off! de Brito-Ashurst, I., Varagunam, M., Raftery, M. J., & Yaqoob, M. M. (2009). Bicarbonate supplementation slows progression of CKD and...

Another dogma shredding trial about diuretics, this time torsemide goes up against king furosemide and its ability to prevent rehospitalization and CV events.

Another dogma shredding trial about diuretics, this time hydrochlorothiazide ability to reduce symptomatic kidney stone events and kidney stone growth gets put under the knife.

The diuretic comparison project is a large, well done, pragmatic trial, that puts to rest the debate of HCTZ versus chlorthalidone. Listen to the Filtrate wrestle with their own cognitive dissonance.

Welcome to the NephMadness PodCrawl The idea behind a podcrawl is for a variety of podcasts to coordinate on timing and topic to push a theme and get each other’s listeners to explore all of the podcasts. One of the first goals behind NephMadness was to build a community and in the early years of Twitter, NephMadness was central to the formation of #NephTwitter and defining the ethos that makes our online community kind, intelligent, vibrant, and interesting. The NephMadness Podcrawl hopes...

Welcome to the NephMadness PodCrawl The idea behind a podcrawl is for a variety of podcasts to coordinate on timing and topic to push a theme and get each other’s listeners to explore all of the podcasts. One of the first goals behind NephMadness was to build a community and in the early years of Twitter, NephMadness was central to the formation of #NephTwitter and defining the ethos that makes our online community kind, intelligent, vibrant, and interesting. The NephMadness Podcrawl hopes to...

MYTEMP is the largest dialysis trial. 15000 patients, 4.3 million dialysis treatments. We bring in lead PI Amit Garg to help break it down the trial and its implications.

For years there has been a growing dogma that if you stop the Renin Angiotensin inhibition when the GFR gets low you can delay dialysis. STOP ACE put the dogma to the test. The results are...meh.

EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that, amazingly, were still unanswered.

After a 2 year hiatus, Kidney Week returned with a great meeting, even if it was in Orlando. Relive some of the highlights with the Filtrate.

Freely Filtered 051: ADVOR turns the practice of sequential nephron blockade on its head by blocking the proximal tubule before the loop of Henle. Does it work? Join The Filtrate as we dissect the latest diuretic RCT.

The Filtrate looks at a trial that tries to dissect the bumps in creatinine we regularly see with Pip/Tazo. Is it AKI or pseudonephrotoxicity?

The Filtrate look at the latest contribution to Fluid Wars, this one looking at late resuscitation.

SODIUM-HF is the largest and longest RCT done looking at sodium restriction heart failure. The top line results show no effect but the more you look at the study the more problematic it is. The Filtrate take it to task.

TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because of excess adverse events to a safe and effective therapy with just a few tweeks. Amazing turn around. Join the Filtrate as we put TESTING to the test with study author Sean Barbour.

The Filtrate: Joel Topf Nayan Arora Sophia Ambruso Swapnil Hiremath Josh Waitzman Special Guest: Natalie Bello Director of Hypertension Research at Cedars Sinai Editor: Nayan Arora Show Notes: NephJC summary of CHAP CHiPS TV show CHIPS study: Less-Tight versus Tight Control of Hypertension in Pregnancy Prevention, Diagnosis, and Management of Hypertensive Disorders of Pregnancy: a Comparison of International Guidelines (Pubmed) SFLT in preeclampsia from where else but NephMadness and...